Mereo BioPharma Group Future Growth
Future criteria checks 5/6
Mereo BioPharma Group is forecast to grow earnings and revenue by 59.2% and 54.1% per annum respectively while EPS is expected to grow by 66.4% per annum.
Key information
59.2%
Earnings growth rate
66.4%
EPS growth rate
| Biotechs earnings growth | 26.7% |
| Revenue growth rate | 54.1% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 23 Dec 2024 |
Recent future growth updates
No updates
Recent updates
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?
Apr 07
Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?
Nov 25Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat
Oct 17Rubric Capital boosts Mereo BioPharma board nominees slate to five
Oct 03Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
Sep 22Mereo activist investor Rubric asks board again to hold general meeting, nominate directors
Sep 14Mereo BioPharma Group regains compliance with Nasdaq's listing rule
Jul 05Mereo BioPharma: Activist Pressure In A Net-Net Biopharma
Jun 17Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development
Dec 08Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study
Apr 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 101 | 11 | -63 | 55 | 3 |
| 12/31/2026 | 42 | -26 | -60 | -12 | 4 |
| 12/31/2025 | 11 | -35 | -10 | -43 | 7 |
| 12/31/2024 | 10 | -30 | N/A | -31 | 7 |
| 9/30/2024 | 1 | -45 | -31 | -30 | N/A |
| 6/30/2024 | 1 | -37 | -21 | -20 | N/A |
| 3/31/2024 | 10 | -26 | -21 | -20 | N/A |
| 12/31/2023 | 10 | -29 | -22 | -21 | N/A |
| 9/30/2023 | 9 | -31 | -29 | -28 | N/A |
| 6/30/2023 | 9 | -32 | -42 | -42 | N/A |
| 3/31/2023 | N/A | -42 | -46 | -46 | N/A |
| 12/31/2022 | N/A | -42 | -47 | -49 | N/A |
| 9/30/2022 | N/A | -31 | -42 | -43 | N/A |
| 6/30/2022 | N/A | -23 | -40 | -41 | N/A |
| 3/31/2022 | 24 | -4 | -25 | -26 | N/A |
| 12/31/2021 | 49 | 17 | -8 | -7 | N/A |
| 9/30/2021 | 49 | -10 | -9 | -8 | N/A |
| 6/30/2021 | 50 | -37 | -10 | -10 | N/A |
| 3/31/2021 | 25 | -131 | -23 | -25 | N/A |
| 12/31/2020 | N/A | -224 | -36 | -39 | N/A |
| 9/30/2020 | N/A | -198 | -35 | -37 | N/A |
| 6/30/2020 | N/A | -177 | -34 | -36 | N/A |
| 3/31/2020 | N/A | -111 | -46 | -47 | N/A |
| 12/31/2019 | N/A | -46 | -61 | -61 | N/A |
| 9/30/2019 | N/A | -41 | -50 | -50 | N/A |
| 6/30/2019 | N/A | -40 | -45 | -45 | N/A |
| 3/31/2019 | N/A | -41 | -38 | -38 | N/A |
| 12/31/2018 | N/A | -41 | -30 | -29 | N/A |
| 9/30/2018 | N/A | -42 | -41 | -39 | N/A |
| 6/30/2018 | N/A | -44 | N/A | -48 | N/A |
| 3/31/2018 | N/A | -50 | N/A | -48 | N/A |
| 12/31/2017 | N/A | -52 | N/A | -43 | N/A |
| 9/30/2017 | N/A | -50 | N/A | -41 | N/A |
| 6/30/2017 | N/A | -47 | N/A | -39 | N/A |
| 3/31/2017 | N/A | -41 | N/A | -37 | N/A |
| 12/31/2016 | N/A | -35 | N/A | -37 | N/A |
| 6/30/2016 | N/A | -39 | N/A | -25 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MREO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: MREO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MREO is expected to become profitable in the next 3 years.
Revenue vs Market: MREO's revenue (54.1% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: MREO's revenue (54.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MREO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 00:32 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mereo BioPharma Group plc is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Yun Zhong | BTIG |
| Julian Harrison | BTIG |